|
gptkbp:instanceOf
|
gptkb:monoclonal_antibody
antineoplastic agent
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvalYear
|
2020
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:triple-negative_breast_cancer
urothelial cancer
|
|
gptkbp:ATCCode
|
L01FX18
|
|
gptkbp:brand
|
gptkb:Trodelvy
|
|
gptkbp:CASNumber
|
1847461-43-1
|
|
gptkbp:contains
|
gptkb:SN-38
humanized monoclonal antibody
topoisomerase I inhibitor
|
|
gptkbp:developedBy
|
gptkb:Gilead_Sciences
gptkb:Immunomedics
|
|
gptkbp:drugClass
|
gptkb:monoclonal_antibody
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
sacituzumab govitecan
|
|
gptkbp:indication
|
metastatic urothelial carcinoma
metastatic triple-negative breast cancer
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:Trop-2
|
|
gptkbp:mechanismOfAction
|
delivers cytotoxic SN-38 to Trop-2 expressing cells
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
vomiting
diarrhea
fatigue
alopecia
neutropenia
|
|
gptkbp:target
|
gptkb:Trop-2
|
|
gptkbp:UNII
|
6Y7T3VZ0NC
|
|
gptkbp:bfsParent
|
gptkb:Trodelvy
|
|
gptkbp:bfsLayer
|
7
|